SEARCH:   Advanced

Blood, 1 December 2004, Vol. 104, No. 12, pp. 3598-3602. Prepublished online as a Blood First Edition Paper on August 17, 2004; DOI 10.1182/blood-2004-03-1107. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-03-1107v1 104/12/3598    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by de Laat, H. B. Articles by de Groot, P. G. Search for Related Content PubMed PubMed Citation Articles by de Laat, H. B. Articles by de Groot, P. G. Related Collections Hemostasis, Thrombosis, and Vascular Biology Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY 2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome H. Bas de Laat, Ronald H.W.M. Derksen, Rolf T. Urbanus, Mark Roest, and Philip G. de Groot From the Department of Haematology, University Medical Centre Utrecht, the Netherlands; the Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, the Netherlands; and the Department of Clinical Chemistry, University Medical Centre Utrecht, the Netherlands. The antiphospholipid syndrome is characterized by the presence of antiphospholipid antibodies in plasma of patients with thromboembolic complications. A major problem in defining the syndrome is that serologic assays to detect antiphospholipid antibodies have a low specificity. We recently published a method that specifically detects lupus anticoagulant (LAC) caused by anti–2-glycoprotein I antibodies. Here, we studied the clinical relevance of detecting 2-glycoprotein I–dependent LAC. Plasma samples were collected from 198 patients with autoimmune diseases. In those samples with a positive partial thromboplastin time–lupus anticoagulant (PTT-LA), a modified activated partial thromboplastin time (aPTT)–based LAC test was performed with cardiolipin as confirming agent. Twenty-five of 58 patients with an aPTT-based LAC were dependent on the presence of anti–2-glycoprotein I antibodies. Presence of 2-glycoprotein I–dependent LAC was almost completely associated with a history of thromboembolic complications (odds ratio, 42.3; 95% confidence interval, 194.3-9.9). An increased frequency of thrombosis was not found in 33 patients with LAC independent of anti–2-glycoprotein I antibodies (odds ratio, 1.6; 95% confidence interval, 3.9-0.8). The use of an LAC assay with cardiolipin as confirming agent strongly improves the detection of patients at risk of thrombosis. Our findings suggest that anti–2-glycoprotein I antibodies with LAC activity are antibodies that are responsible for the thromboembolic complications in the antiphospholipid syndrome. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A Tincani, M Filippini, M Scarsi, M Galli, and P. Meroni European attempts for the standardisation of the antiphospholipid antibodies Lupus, September 1, 2009; 18(10): 913 - 919. [Abstract] [PDF] A Tripodi Testing for lupus anticoagulants: all that a clinician should know Lupus, April 1, 2009; 18(4): 291 - 298. [Abstract] [PDF] B. Giannakopoulos, F. Passam, Y. Ioannou, and S. A. Krilis How we diagnose the antiphospholipid syndrome Blood, January 29, 2009; 113(5): 985 - 994. [Abstract] [Full Text] [PDF] Y. Shen, R Lee, E Frenkel, and R Sarode IgA antiphospholipid antibodies are an independent risk factor for thromboses Lupus, November 1, 2008; 17(11): 996 - 1003. [Abstract] [PDF] S. M. Nelson and I. A. Greer The potential role of heparin in assisted conception Hum. Reprod. Update, November 1, 2008; 14(6): 623 - 645. [Abstract] [Full Text] [PDF] J. H. Rand, X.-X. Wu, A. S. Quinn, P. P. Chen, J. J. Hathcock, and D. J. Taatjes Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-{beta}2-glycoprotein I complexes to phospholipid bilayers Blood, September 1, 2008; 112(5): 1687 - 1695. [Abstract] [Full Text] [PDF] G. W. Moore, S. Rangarajan, and G. F. Savidge The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 332 - 337. [Abstract] [PDF] S van Wissen, B. Bastiaansen, A. Stroobants, E. van den Dool, M. Idu, M Levi, and E. Stroes Catastrophic antiphospholipid syndrome mimicking a malignant pancreatic tumour - a case report Lupus, June 1, 2008; 17(6): 586 - 590. [Abstract] [PDF] A. Tripodi Laboratory Testing for Lupus Anticoagulants: A Review of Issues Affecting Results Clin. Chem., September 1, 2007; 53(9): 1629 - 1635. [Abstract] [Full Text] [PDF] J. J. J. Hulstein, P. J. Lenting, B. de Laat, R. H. W. M. Derksen, R. Fijnheer, and P. G. de Groot {beta}2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation Blood, September 1, 2007; 110(5): 1483 - 1491. [Abstract] [Full Text] [PDF] M. Galli, G. Borrelli, E. M. Jacobsen, R. M. Marfisi, G. Finazzi, R. Marchioli, F. Wisloff, S. Marziali, O. Morboeuf, and T. Barbui Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study Blood, August 15, 2007; 110(4): 1178 - 1183. [Abstract] [Full Text] [PDF] N. Di Simone, P.L. Meroni, M. D'Asta, F. Di Nicuolo, M.C. D'Alessio, and A. Caruso Pathogenic role of anti-{beta}2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin Hum. Reprod. Update, March 1, 2007; 13(2): 189 - 196. [Abstract] [Full Text] [PDF] B. de Laat, X.-X. Wu, M. van Lummel, R. H. W. M. Derksen, P. G. de Groot, and J. H. Rand Correlation between antiphospholipid antibodies that recognize domain I of {beta}2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5 Blood, February 15, 2007; 109(4): 1490 - 1494. [Abstract] [Full Text] [PDF] B. Giannakopoulos, F. Passam, S. Rahgozar, and S. A. Krilis Current concepts on the pathogenesis of the antiphospholipid syndrome Blood, January 15, 2007; 109(2): 422 - 430. [Abstract] [Full Text] [PDF] J. H. Rand The Antiphospholipid Syndrome Hematology, January 1, 2007; 2007(1): 136 - 142. [Abstract] [Full Text] [PDF] B de Laat, R H W M Derksen, I J Mackie, M Roest, S Schoormans, B J Woodhams, P G de Groot, and W L van Heerde Annexin A5 polymorphism (-1C->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome Ann Rheum Dis, November 1, 2006; 65(11): 1468 - 1472. [Abstract] [Full Text] [PDF] B. de Laat, R. H. W. M. Derksen, M. van Lummel, M. T. T. Pennings, and P. G. de Groot Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change Blood, March 1, 2006; 107(5): 1916 - 1924. [Abstract] [Full Text] [PDF] D. Feinbloom and K. A. Bauer Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2043 - 2053. [Abstract] [Full Text] [PDF] O. Safa, C. T. Esmon, and N. L. Esmon Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies Blood, September 1, 2005; 106(5): 1629 - 1635. [Abstract] [Full Text] [PDF] M. A. Vickers and M. Greaves The cryptic path from epitope to clot: a story of 2 domains? Blood, February 15, 2005; 105(4): 1371 - 1372. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020